- Home
- GCV vs AVTX Comparison
GCV vs AVTX Comparison
Compare GCV & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCV
- AVTX
- Stock Information
- Founded
- GCV 1988
- AVTX 2011
- Country
- GCV United States
- AVTX United States
- Employees
- GCV N/A
- AVTX N/A
- Industry
- GCV Finance/Investors Services
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- GCV Finance
- AVTX Health Care
- Exchange
- GCV Nasdaq
- AVTX Nasdaq
- Market Cap
- GCV 76.1M
- AVTX 70.9M
- IPO Year
- GCV N/A
- AVTX 2015
- Fundamental
- Price
- GCV $3.87
- AVTX $6.75
- Analyst Decision
- GCV
- AVTX Strong Buy
- Analyst Count
- GCV 0
- AVTX 4
- Target Price
- GCV N/A
- AVTX $33.00
- AVG Volume (30 Days)
- GCV 57.9K
- AVTX 133.9K
- Earning Date
- GCV 01-01-0001
- AVTX 11-07-2024
- Dividend Yield
- GCV 13.04%
- AVTX N/A
- EPS Growth
- GCV N/A
- AVTX N/A
- EPS
- GCV N/A
- AVTX N/A
- Revenue
- GCV N/A
- AVTX $820,000.00
- Revenue This Year
- GCV N/A
- AVTX N/A
- Revenue Next Year
- GCV N/A
- AVTX N/A
- P/E Ratio
- GCV N/A
- AVTX N/A
- Revenue Growth
- GCV N/A
- AVTX N/A
- 52 Week Low
- GCV $3.15
- AVTX $4.01
- 52 Week High
- GCV $4.58
- AVTX $34.46
- Technical
- Relative Strength Index (RSI)
- GCV 50.78
- AVTX 35.20
- Support Level
- GCV $3.73
- AVTX $6.04
- Resistance Level
- GCV $3.91
- AVTX $7.17
- Average True Range (ATR)
- GCV 0.08
- AVTX 0.83
- MACD
- GCV 0.01
- AVTX -0.01
- Stochastic Oscillator
- GCV 72.22
- AVTX 30.33
About GCV Gabelli Convertible and Income Securities Fund Inc. (The)
GABELLI CONVERTIBLE & INCOME SECURITIES FUND INC is a diversified closed-end management investment company. Its investment objective is to seek a high level of total return through a combination of current income and capital appreciation by investing in convertible securities. The company invests in various portfolios such as Health Care, Financial Services, Real Estate Investment Trust, Energy and Utilities, Telecommunications, Food and Beverage, Aerospace and Automotive and others. All the operation of the group is operated through the regions of United States.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).